IE 11 is a very old Browser and it`s not supported on this site

top stories

bb entrepreneur private

Bellevue expands its product offering in the field of Private Equity

Bellevue Group AG is strengthening its private equity arm with the launch of the BB Entrepreneur Private strategy, an investment vehicle focused on growth financing for small and mid-sized Swiss companies. In addition to the successful venture capital fund BB Pureos Bioventures, Bellevue is now launching a new initiative to strengthen the Swiss SME landscape.

read article

bb pureos bioventures

Venture Capital Fund raises USD 168 millions and demand remains strong

BB Pureos Bioventures (Pureos) was launched two years ago as venture capital fund focused on private biotech companies developing novel medicines for severe diseases. Bellevue Asset Management AG, announced the closing of its first fund, BB Pureos Bioventures L.P. («Pureos») after receiving capital commitments of USD 168 mn. In view of the capital commitments received in early 2021 and the persisting high levels of interest, this fund will likely pass the USD 200 mn threshold at the end of March 2021, when the final closing is scheduled.

read article

bb biotech

Interview with Dr. Daniel Koller, Head Investment Team BB Biotech

Dr. Daniel Koller is looking back on the challenging pandemic year 2020 in a video interview. First he discusses the groundbreaking success of the biotech industry. It has developed successful and safe vaccines in record time and is leading the fight against the SARS-CoV-2 virus pandemic with these vaccines and therapeutic antibodies. In addition, he explains why BB Biotech had already had invested in Moderna in 2018 and what opportunity he sees for the mRNA technology in the future. Finally he gives an insight into the portfolio and tells why he has added Biogen, in the portfolio.

watch interview

Bellevue Group uses cookies to improve website usability and ensure the best possible user experience.Use of cookies & disclaimer